Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Lung tracking system provides vital robotic radiosurgery tool

Accuray : 23 July, 2007  (New Product)
Accuray’s Xsight Lung Tracking System, which is designed for the non-invasive treatment of lung tumours, is quickly gaining clinical acceptance with more than 97 percent of new US customers including Xsight Lung in their purchase of a new CyberKnife Robotic Radiosurgery System.
Further extending the CyberKnife System’s suite of products targeted toward the treatment of lung tumours is Accuray’s Monte Carlo dose calculation algorithm, which is pending FDA 510(k) clearance.

“We have seen great success using Xsight Lung Tracking System to treat lung cancer non-invasively because of its ability to lock onto and deliver radiation to the tumour while minimising damage to healthy tissue,” said James Schwade, MD, executive director of the CyberKnife Centers of Miami and Palm Beach. “The CyberKnife System with Xsight Lung Tracking allows us to break down the barriers to lung cancer treatment. We are now able to give new hope to patients - such as the elderly and those considered medically or surgically inoperable - who previously would have had no other option.”

Working seamlessly with Accuray’s CyberKnife System and Synchrony Respiratory Tracking System, Xsight Lung Tracking is the only system that uses the body's soft tissue to directly track targets with radiosurgical accuracy. The systems delivers highly specialised soft tissue tracking by using the actual image intensity of the lung tumour to target the beam, therefore eliminating the need in some cases for implanted fiducial markers.

An additional tool in the treatment of lung cancer is Accuray’s Monte Carlo dose calculation methodology, which is currently pending FDA 510(k) clearance. Accuray’s Monte Carlo dose calculation is designed to be fast and accurate, enabling clinicians to more precisely determine, in a matter of minutes, the intensity of radiation to be delivered in areas where tissue densities vary. This is particularly critical with lung cancer, since healthy tissue surrounding tumours is made up of air cavities, which are less dense than the solid tumours.

“The addition of Monte Carlo dose calculation to Accuray’s product portfolio will bring the gold standard of dose calculation to the CyberKnife System,” said Charlie Ma, Ph.D, director of radiation physics at Fox Chase Cancer Center in Philadelphia, USA. “Incorporating Monte Carlo dose calculation capabilities into the CyberKnife System will enable clinicians to quickly and precisely plan treatment and accurately determine the resulting radiation delivered to tumours.”

“The combination of Monte Carlo dose calculation, Xsight Lung Tracking and Synchrony Respiratory Tracking will take the CyberKnife System’s ability to treat lung tumours to a new, far superior level,” said Eric P Lindquist, senior vice president and chief marketing officer of Accuray. “We are extremely excited about the high level of clinical acceptance for the CyberKnife System and Xsight Lung, with purchases coming in from cancer clinics around the world. These technologies are making it possible to effectively treat lung tumours in a wider array of patients. When FDA 510(k) clearance is obtained for the Monte Carlo dose calculation algorithm, clinicians will have all the best tools available to them in
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo